Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07038200 · ClinicalTrials.gov registry record · Phase 3

A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD

A Phase 3 study of Facioscapulohumeral Muscular Dystrophy and FSHD, sponsored by Avidity Biosciences.

Recruiting
Registry status
Phase 3
Development phase
200
Enrollment target
20
Study locations

NCT07038200 is a Phase 3 study of Facioscapulohumeral Muscular Dystrophy and FSHD that is actively recruiting participants, run by Avidity Biosciences. The registered enrollment target is 200 participants, below the 1,479-participant average among 6 other Facioscapulohumeral Muscular Dystrophy trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 17 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07038200, a Phase 3 study of Facioscapulohumeral Muscular Dystrophy and FSHD, is actively recruiting participants, sponsored by Avidity Biosciences.

RECRUITING
Registry status
Phase 3
Development phase
200 participants
Enrollment target
20
Study locations

Study Summary

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)

Conditions Studied

Facioscapulohumeral Muscular Dystrophy FSHD Fascioscapulohumeral Muscular Dystrophy FSHD - Facioscapulohumeral Muscular Dystrophy FSHD1 FSHD2 Facioscapulohumeral Muscular Dystrophy 1 Fascioscapulohumeral Muscular Dystrophy Type 1 Fascioscapulohumeral Muscular Dystrophy Type 2 Facioscapulohumeral Dystrophy

Interventions

  • DRUG Placebo
  • DRUG AOC-1020

Study Locations (20)

California

  • University of California Irvine - Orange
  • Stanford University - Palo Alto

Alberta

  • University of Calgary - Cumming School of Medicine - Calgary
  • University of Alberta Hospital - Edmonton

Other

  • National Hospital Organization Osaka Toneyama Medical Center - Osaka
  • The University of Osaka Hospital - Osaka

Colorado

  • University of Colorado - Denver

Florida

  • University of Florida - Gainesville

Iowa

  • University of Iowa - Iowa City

Kansas

  • Kansas University Medical Center - Kansas City

Maryland

  • Kennedy Krieger Institute - Baltimore

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2025-06-10
Est. Completion 2028-07
Phase Phase 3

Sponsor

Avidity Biosciences

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07038200

The ClinicalTrials.gov registry entry for NCT07038200 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,479-participant average among 6 other Facioscapulohumeral Muscular Dystrophy trials with a reported enrollment target (86% lower). The listed sponsor is Avidity Biosciences, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Facioscapulohumeral Muscular Dystrophy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07038200 reports 20 study locations spanning 17 distinct geographic areas - top geographies include California, Alberta, Other.

Frequently Asked Questions

What is clinical trial NCT07038200 about?

NCT07038200 is a clinical study titled "A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD". A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)

What is the current status of trial NCT07038200?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2025-06-10. Estimated completion is 2028-07.

What conditions does trial NCT07038200 study?

This clinical trial studies the following conditions: Facioscapulohumeral Muscular Dystrophy, FSHD, Fascioscapulohumeral Muscular Dystrophy, FSHD - Facioscapulohumeral Muscular Dystrophy, FSHD1.

What interventions are being tested in trial NCT07038200?

The interventions under investigation include: Placebo (DRUG), AOC-1020 (DRUG).

Who is sponsoring clinical trial NCT07038200?

This trial is sponsored by Avidity Biosciences, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07038200 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Iowa, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Facioscapulohumeral Muscular Dystrophy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Facioscapulohumeral Muscular Dystrophy

All registered trials for this condition

FSHD

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.